Several studies have demonstrated that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR–TKI) treatment of patients with advanced EGFR–mutant NSCLC yields superior survival outcomes to chemotherapy (2–4). Here, EGFR is linked to non-small cell lung carcinoma.